Literature DB >> 2907464

Pharmacokinetics and enterohepatic circulation of 2-n-propyl-4-pentenoic acid in the rat.

K Singh1, J M Orr, F S Abbott.   

Abstract

The pharmacokinetics of 4-ene-valproic acid (4-ene-VPA), a putative hepatotoxic metabolite of the anticonvulsant valproic acid (VPA), were studied in normal and bile-exteriorized rats. A single iv bolus dose of 20 or 100 mg/kg of 4-ene-VPA was administered to each rat. Plasma decline of 4-ene-VPA was apparently monoexponential at the low dose and nonlinear at the high dose. In normal rats, 4-ene-VPA was recycled in the plasma due to enterohepatic circulation (EHC). A time lag pharmacokinetic model was used to describe the plasma profile, including the appearance of a secondary plasma peak, in normal animals receiving the low dose of 4-ene-VPA. Total apparent plasma clearance was 8.67 ml/min.kg at the low dose and 5.89 ml/min.kg at the high dose. EHC was abolished in bile-exteriorized animals. In these rats, the apparent plasma elimination half-life increased from 12.7 to 18.8 min and plasma clearance decreased from 11.4 to 7.41 ml/min.kg with a 5-fold increase in the dose. 4-ene-VPA was largely eliminated in urine and bile as conjugates. In normal rats, 22% and 28% of the low and high dose, respectively, were eliminated in urine. Approximately 29% of the low dose and 21% of the high dose were recovered in bile of the rat. Like the parent drug VPA, 4-ene VPA induced dose-dependent choleresis in the rat. The pharmacokinetics of 4-ene-VPA in the rat were similar to those reported for VPA.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2907464

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  8 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

2.  Physiologic and metabolic influences on enterohepatic recirculation: simulations based upon the disposition of valproic acid in the rat.

Authors:  G M Pollack; K L Brouwer
Journal:  J Pharmacokinet Biopharm       Date:  1991-04

3.  Analysis of enterohepatic circulation of cefixime in rat by fast inverse Laplace transform (FILT).

Authors:  K Yamaoka; M Kanba; Y Toyoda; Y Yano; T Nakagawa
Journal:  J Pharmacokinet Biopharm       Date:  1990-12

4.  A recirculatory model with enterohepatic circulation by measuring portal and systemic blood concentration difference.

Authors:  Toshiya Moriwaki; Hiroyuki Yasui; Akira Yamamoto
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-04       Impact factor: 2.745

5.  Preclinical pharmacology of the antitumor agent O-6-methylguanine in CDF1 mice.

Authors:  V I Avramis; K K Chan; M M Solorzano; Z L Chen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Evaluation of intestinal absorption into the portal system in enterohepatic circulation by measuring the difference in portal-venous blood concentrations of diclofenac.

Authors:  K Tabata; K Yamaoka; T Fukuyama; T Nakagawa
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

Review 7.  Differentiation between valproate-induced anticonvulsant effect, teratogenicity and hepatotoxicity. Aspects of species variation, pharmacokinetics, metabolism and implications of structural specificity for the development of alternative antiepileptic agents such as delta 2-valproate.

Authors:  H Nau; H Siemes
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

8.  Effects of amoxicillin/clavulanic acid on the pharmacokinetics of valproic acid.

Authors:  Soo-Yun Lee; Wooseong Huh; Jin Ah Jung; Hye Min Yoo; Jae-Wook Ko; Jung-Ryul Kim
Journal:  Drug Des Devel Ther       Date:  2015-08-10       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.